Floris van Delft

Head, R&D Synaffix

Seminars

Tuesday 4th November 2025
Synaffix/Lonza End-to-End Offering to Best-in-Class Targeted-Therapies Based on GlycoConnect® & HydraSpace® Technologies
3:30 pm
  • Exploring how GlycoConnect® and HydraSpace® technologies enable ADCs with best-in-class therapeutic potential
  • Sharing clinical development insights on the rapidly advancing pipeline of GlycoConnect® ADCs by partners
  • Discussing technology expansion towards bispecific (bYlok®) and dual warhead ADCs with compelling in vivo preclinical data
  • Presenting unprecedented mRNA exon skipping and dystrophin restoration in preclinical mouse model for Duchenne muscular dystrophy
Floris van Delft - 16th World ADC San Diego